# Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

> **NCT04421222** · PHASE1 · TERMINATED · sponsor: **ESSA Pharmaceuticals** · enrollment: 71 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** EPI-7386 (QD)
- **DRUG:** EPI-7386 (BID)
- **DRUG:** Abiraterone acetate
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT04421222
- **Lead sponsor:** ESSA Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-23
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-12-03
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Study was terminated early due to a lack of improved efficacy.
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421222, "Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04421222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*